
Center for Neuroendocrine Tumors
The UCSF Center for Neuroendocrine Tumors provides comprehensive care for patients with all types of neuroendocrine tumors (NETs). Arising from cells that have traits of both nerve cells and endocrine cells, these rare tumors may produce hormones and can develop in many parts of the body, including the head and neck, lungs, pancreas and digestive tract.
We're equipped to handle any NET, no matter where it appears in the body or how it behaves. Our team includes surgeons, medical oncologists, radiation oncologists, radiologists, cardiologists, endocrinologists, symptom management experts, genetic counselors, nutritionists, psychologists, social workers and other specialists. We work together to provide patients with a precise diagnosis and treatment plan tailored to their particular case and needs.
All of our patients can expect to receive the latest and most effective therapies available for their condition. For a patient with a pancreatic NET, for example, the best treatment might involve minimally invasive surgery to remove the tumor. A patient with a gastrointestinal tumor might benefit from peptide receptor radionuclide therapy (PRRT), a new radiation technique that targets cancer cells. And we might use advanced screening tools, such as the UCSF500 Cancer Gene Panel test, to identify the precise biology behind another patient's tumor.
Our goal is to deliver world-class care from a holistic perspective. We make sure that our patients and their families have the support they need to face the physical, emotional and financial challenges that can arise after a cancer diagnosis. UCSF offers a wide range of cancer support services, including a bimonthly education and support group for patients with NETs and their loved ones.
Our locations
Our team
Clinical trials
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Recruiting
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
Proportion of patients who achieve as their best overall response according to Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1 criteria: Stable disease (SD), partial response (PR), confirmed Complete Response (CR), or...
Recruiting
Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...
The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Fisher's exact test will be...
Recruiting
Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine...
The point estimate and 95% confidence interval of overall response rate will be obtained for each of the three liver-directed therapy groups (cryoablation, transarterial embolization(TAE) , radioembolization (RE)) separately. The ...
Recruiting
Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver...
Any adverse events grade ≥ 3 will be reviewed by the treating interventional radiologist and medical oncologist within 24 hours of being informed event. If none of the 3 patients in a cohort experiences a DLT, another 3 patients w...
Recruiting
Phase II Trial of AZD6738 Alone and in Combination With Olaparib
ORR will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized valu...
Recruiting
U.S. News rankings
-
Best hospital in Northern California
-
Best in Northern California in cancer care
Accreditations & memberships
-
National Cancer Institute
The National Cancer Institute has designated UCSF a comprehensive cancer center, its highest ranking. This designation is awarded to centers that demonstrate scientific excellence and the ability to conduct cancer research across many disciplines.
-
Commission on Cancer
UCSF's cancer programs have been accredited by the American College of Surgeons' Commission on Cancer (CoC) since 1933. The CoC is a consortium of groups dedicated to improving cancer patients' survival and quality of life via research, education and better medical care.
-
National Comprehensive Cancer Network
UCSF is a founding member of the National Comprehensive Cancer Network, an alliance of the world’s top cancer centers. The network brings together leaders in treatment and research to improve the quality, effectiveness and efficiency of cancer care.
Support services
Plan your visit
What to Bring
- Photo I.D.
- Health insurance card
- Insurance authorization, if required
- Doctor's referral, if required
- Recent test results related to your condition
- List of your medications, including dosages, plus any you're allergic to
- List of questions you may have
- Device or paper for taking notes

International Services
If you live in another country and are coming to UCSF for medical
treatment, our patient liaisons can help coordinate all aspects of your visit.

Interpreters
UCSF offers language services at no charge for patients with limited
English, as well as for patients who are deaf or have trouble hearing.

Hospital Stays
Checking into the hospital? Find helpful information by clicking on the relevant “Your Hospital Stay” booklet: Mission Bay, Parnassus or Mount
Zion.

Your Doctor Visit
See our top 10 tips for making your UCSF doctor’s appointment as stress-free and productive as possible.
Learn more